Research Article

Brain and immune system: KURU disease a toxicological process?

Luisetto M*, Behzad Nili-Ahmadabadi, Ghulam Rasool Mashori, Ahmed Yesvi, Ram Kumar Sahu, Heba Nasser, Cabianca luca and Farhan Ahmad Khan

Published: 03 May, 2018 | Volume 2 - Issue 1 | Pages: 014-027

Starting from observation of pathogenesis of KURU disease we try to investigate the immunologic role played by central nervous systems. A deeply knowledge in the transmission model of this pathology can be an imaging/diagnostic tool to Verify the progression of this prion molecule from gastro intestinal systems to the brain. (After cannibalistic behavior). The prions can be considered a sort of trace ant in KURU to monitoring this process and immune- brain relationship. Interesting information can be obtained useful to produce new pharmacological strategies in some other degenerative brain disease involving innate immune system activation.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001010 Cite this Article Read Full Article PDF


Prion disease pathogenesis; Transmissible spongiform encephalopathy; Innate immune system brain disease; Neurodegenerative disease


  1. Luisetto M. Brain response in some systemic immune condition-Toxicological aspects. Insights Clin Cell Immunol. 2017; 1: 005-008. Ref.: https://goo.gl/Rp9s2K
  2. Shirley Lindenbaum. Understanding kuru: the contribution of anthropology and medicine. Philos Trans R Soc Lond B Biol Sci. 2008; 363: 3715-3720. Ref.: https://goo.gl/LjygFe
  3. Haïk S, Brandel JP. Infectious prion diseases in humans: cannibalism, iatrogenicity and zoonoses. Infect Genet Evol. 2014; 26: 303-312. Ref.: https://goo.gl/w2c1y5
  4. D Carleton Gajdusek. Philos Kuru and its contribution to medicine. Trans R Soc Lond B Biol Sci. 2008; 363: 3697-3700. Ref.: https://goo.gl/RRWb73
  5. Barry M. Bradford and Neil A. Mabbott. Prion Disease and the Innate Immune System. Viruses. 2012; 4: 3389-3419. Ref.: https://goo.gl/kjNGgd
  6. Patrik Brundin, Jiyan Ma and Jeffrey H Kordower. How strong is the evidence that Parkinson’s disease is a prion disorder? Curr Opin Neurol. 2016; 29: 459-466. Ref: https://goo.gl/MqEBuF
  7. Thomas Korn, Axel Kallies. T cell responses in the central nervous system. Nature Reviews Immunology. 17: 179-194. Ref.: https://goo.gl/LJTz2F
  8. Iannacone M, Moseman EA, Tonti E, Bosurgi L, Junt T, et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature. 2010; 465:1079-1083. Ref.: https://goo.gl/wPRjQi
  9. Ironside JW, Ritchie DL, Head MW2. Prion diseases. Handb Clin Neurol. 2017; 145: 393-403.
  10. Iwasaki Y, Saito Y, Aiba I, Kobayashi A, Mimuro M, et al. An autopsied case of MV2K + C-type sporadic Creutzfeldt-Jakob disease presenting with widespread cerebral cortical involvement and Kuru plaques. Neuropathology. 2017; 37: 241-248.Ref.: https://goo.gl/uUaFfr
  11. Rayman JB, Kandel ER. Functional Prions in the Brain. Cold Spring Harb Perspect Biol. 2017; 3: 9. Ref.: https://goo.gl/8RBUQJ
  12. David C. Wraith and Lindsay B. Nicholson. The adaptive immune system in diseases of the central nervous system. J Clin Invest. 2012; 122: 1172-1179. Ref.: https://goo.gl/gfeiHo
  13. Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature. 2018; 556: 332-338. Ref.: https://goo.gl/fCZtKc
  14. Robert Dantzer. Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. 2017. Ref.: https://goo.gl/WgT9Gn
  15. Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000Res. 2017; 6: 1604. Ref.: https://goo.gl/nyTDYn
  16. Gail Chan, Charles C White, Phoebe A Winn, Maria Cimpean, Joseph M Replogle, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nature Neuroscience. 2015; 18: 1556-1558. Ref.: https://goo.gl/nnNw3o
  17. Paul S, Planque S, Nishiyama Y. Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide. J Clin Immunol. 2010; 1: S43-S49. Ref.: https://goo.gl/XWMnfz
  18. Holmes BB, Diamond MI. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem. 2014; 289: 19855-19861. Ref.: https://goo.gl/fnZyzH
  19. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, et al. Regulation of Tau Pathology by the Microglial Fractalkine Receptor. Neuron. 2010; 68: 19-31. Ref.: https://goo.gl/eZyGR3
  20. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16: 358-372. Ref.: https://goo.gl/Jm17rH
  21. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol. 2015; 16: 229-236. Ref.: https://goo.gl/dbfgbk
  22. Luisetto M. Intra- Local Toxicology Aspect Time Related in Some Pathologic Conditions. Open Acc J of Toxicol. 2017; 2. Ref.: https://goo.gl/nzZB6b
  23. Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol. 2012; 165: 1246-1259. Ref.: https://goo.gl/s1xMkE

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?